<i>Interleukin-28</i>and hepatitis C virus genotype-4: Treatment-induced clearance and liver fibrosis

Derbala, Moutaz; Rizk, Nasser; Shebl, Fatima M; Al‐Kaabi, Saad; El-Dweik, N.; John, Anil; Sharma, Manik; Yaqoob, R.; Almohanadi, Muneera; Butt, Mohammed T.; Alejji, Khaled

doi:10.3748/wjg.v18.i47.7003

Cited by 16 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the favourable genotypes of rs12979860 and rs8099917 were found to be present in 35.3 and 62.2% of the subjects respectively. The genotypic pattern of both SNPs was similar to that described by other studies in three countries in Middle East (20)(21)(22). In Egypt, Al Awady and colleagues reported rs12979860 CC in 86% of individuals who cleared HCV-4 infection and 13% of individuals with persistent infection following the acute phase (23).…”

Section: Discussionsupporting

confidence: 85%

“…In this study, SVR was achieved in 43.4% of 119 treated cases with HCV‐4, including 6 cases that discontinued therapy because of intolerable side effects. This SVR rate was comparable to 48 and 49.6% in two cohorts with HCV‐4 . Although rs12979860 CC was the only genotype significantly associated with SVR in our study and that reported by Hendy and colleagues , CC and CT genotypes were equally good at predicting SVR, as found by Derbala in Qatar .…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Ragheb

Nemr²,

Kishk³

et al. 2013

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 85%

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Ragheb

Nemr²,

Kishk³

et al. 2013

Liver International

View full text Add to dashboard Cite

show abstract

“…The study shows that in the observed cohort, the HCV4 genotype is the most frequent, with a prevalence higher than the one described in literature in Europe and Italy (55.2 % vs. about 5-10 %) [25,26].…”

Section: Discussioncontrasting

confidence: 56%

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment

Nosotti¹,

Petrelli²,

Genovese³

et al. 2016

J Immigrant Minority Health

View full text Add to dashboard Cite

Aims of the study are to investigate, in a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome. 365 patients with HCV infection were observed between 2013 and 2014. Demographic, virological, biochemical, and genetic characteristics of each patient were investigated. Liver fibrosis was assessed by transient elastometry. Mean age of the patients (72.9 % males, 27.1 % females) is 50 years. 91.5 % % of patients are Caucasian, 8.5 % African. In the patients with HCV1 and HCV4 a higher frequency of IL28B CT is observed with a prevalence of 52.1 and 61.8 % respectively. As regards ethnic group, African people have a prevalence of 35.5 % for CC, while Caucasians have a prevalence of 23.8 % for CC. In our cohort, IL28B polymorphism does not show significant differences among ethnic groups and in HCV1 and HCV4 genotypes. As described in literature, IL28B CC genotype is confirmed as predictor of sustained virological response in both Caucasians and Africans. A significant correlation between liver fibrosis and IL28B polymorphism emerges.

show abstract

“…Nine studies with a total of 1,893 patients [572 (30%) CC and 1321 (70%) CT/TT] assessed SVR in rs12979860 CC versus CT/TT (Figure 6a)[27, 37–39, 41, 42, 80, 81, 88]. …”

Section: Resultsmentioning

confidence: 99%

Meta-analysis

Yee

Nguyen

Zhang

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be ~20–70%. However, many of these studies are limited by different study designs and small sample sizes. Aim Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative fashion. Methods A comprehensive literature search in MEDLINE and EMBASE for ‘genotype 4’ was conducted in November 2013. Abstracts from AASLD, APASL, DDW, and EASL in 2012/2013 were reviewed. Inclusion criteria were original studies with ≥25 treatment-naïve HCV-4 patients treated with PEG IFN+RBV. Exclusion criteria were co-infection with HIV, HBV, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (p-value <0.05) and I-squared statistic (>50%). Results We included 51 studies (11,102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% (95% CI: 50–55%) (Q-statistic = 269.20, p<0.05; I2 = 81.43). On sub-group analyses, SVR was significantly associated with lower viral load, OR 3.05 (CI 1.80–5.17, p<0.001); mild fibrosis, OR 3.17 (CI 2.19–4.59, p<0.001); and favorable IL28B polymorphisms, rs12979860 CC versus CT/TT, OR 4.70 (CI 2.87–7.69, p<0.001), and rs8099917 TT versus GT/GG, OR 5.21 (CI 2.31–11.73, p<0.001). Conclusions HCV-4 patients treated with PEG IFN+RBV may expect SVR rate of ~50%. Lower viral load, mild fibrosis, and favorable IL28B (rs12979860 CC and rs8099917 TT) are positively associated with SVR.

show abstract

Interleukin-28and hepatitis C virus genotype-4: Treatment-induced clearance and liver fibrosis

Abstract: In HCV-genotype 4 patients, rs12979860 is a sensitive predictor of viral clearance, independent of viral load, age, gender or fibrosis, with no similar relation to severity of fibrosis.

Cited by 16 publications

References 25 publications

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment

Meta-analysis

Contact Info

Product

Resources

About